Modular Medical

Modular Medical, Inc. is a medical device company developing a next-generation, low-cost insulin pump technology intended to expand access to insulin pump therapy for people with diabetes. The company is pursuing U.S. FDA clearance for its modular pump platform, targeting the type 1 and insulin-requiring type 2 diabetes markets with a simplified, affordable patch-pump design. Following the March 31, 2026 1-for-30 reverse stock split (reducing outstanding shares from 139.8M to approximately 4.66M to address Nasdaq's $1.00 minimum bid price requirement), the company continues to trade on Nasdaq under the MODD symbol. Modular Medical's pipeline targets the broader insulin-delivery market currently served by incumbents including Tandem Diabetes Care, Insulet, and Medtronic Diabetes.